KELLY WILSON: Open Payments
NPI 1124318027 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,288 in 65 payments from 14 companies in 2025. Trend: 2023 $1,105 · 2024 $1,177 · 2025 $1,288
Food & beverage: $1,247Education: $41
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 14 | $281 |
| GlaxoSmithKline, LLC. | 20 | $209 |
| Amgen Inc. | 10 | $167 |
| Ionis Pharmaceuticals, Inc. | 3 | $155 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $98 |
| Novartis Pharmaceuticals Corporation | 4 | $90 |
| GENZYME CORPORATION | 2 | $52 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $49 |
| CSL Behring | 2 | $46 |
| Galderma Laboratories, L.P. | 2 | $43 |
Products named: DUPIXENT, TEZSPIRE, DAWNZERA, TRELEGY ELLIPTA, NUCALA, OFEV, NEFFY, Rhapsido.
Industry payments across CA — which companies pay providers there.
